Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,549 as of Thursday, May 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,112 issues advancing vs. 834 declining with 184 unchanged.

The Health Services industry currently sits up 0.9% versus the S&P 500, which is up 0.4%. Top gainers within the industry include WuXi PharmaTech (Cayman ( WX), up 6.6%, Icon ( ICLR), up 3.9%, Community Health Systems ( CYH), up 3.6%, Smith & Nephew ( SNN), up 1.4% and ResMed ( RMD), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Edwards Lifesciences ( EW) is one of the companies pushing the Health Services industry lower today. As of noon trading, Edwards Lifesciences is down $1.95 (-2.3%) to $83.03 on average volume. Thus far, 676,301 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $83.01-$85.23 after having opened the day at $85.10 as compared to the previous trading day's close of $84.98.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $9.0 billion and is part of the health care sector. Shares are up 29.2% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Edwards Lifesciences a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Edwards Lifesciences Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, CR Bard ( BCR) is down $1.54 (-1.0%) to $145.92 on average volume. Thus far, 424,251 shares of CR Bard exchanged hands as compared to its average daily volume of 823,900 shares. The stock has ranged in price between $145.53-$147.50 after having opened the day at $147.50 as compared to the previous trading day's close of $147.46.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $11.2 billion and is part of the health care sector. Shares are up 10.1% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts that rate CR Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates CR Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CR Bard Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.12 (-0.9%) to $12.68 on average volume. Thus far, 5.1 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 12.1 million shares. The stock has ranged in price between $12.68-$12.83 after having opened the day at $12.80 as compared to the previous trading day's close of $12.80.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $16.7 billion and is part of the health care sector. Shares are up 6.5% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null